S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Price, News & Analysis

$25.40
-0.14 (-0.55%)
(As of 03/28/2024 ET)
Today's Range
$25.24
$25.62
50-Day Range
$22.24
$26.42
52-Week Range
$16.54
$29.25
Volume
83,692 shs
Average Volume
85,880 shs
Market Capitalization
$377.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
16.1% Upside
$29.50 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.84
Upright™ Environmental Score
News Sentiment
0.30mentions of Anika Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
20.54%
From $1.12 to $1.35 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.43 out of 5 stars

Medical Sector

333rd out of 938 stocks

Surgical & Medical Instruments Industry

42nd out of 95 stocks

ANIK stock logo

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

ANIK Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
ADC Therapeutics Q4 Earnings Preview
Earnings Outlook For Anika Therapeutics
Anika Therapeutics Inc (AKP.BE)
Anika Therapeutics, Inc. (ANIK)
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
345
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$29.50
High Stock Price Target
$37.00
Low Stock Price Target
$22.00
Potential Upside/Downside
+16.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-82,670,000.00
Pretax Margin
-51.20%

Debt

Sales & Book Value

Annual Sales
$166.66 million
Cash Flow
$4.93 per share
Book Value
$14.50 per share

Miscellaneous

Free Float
13,981,000
Market Cap
$377.19 million
Optionable
Optionable
Beta
0.75

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 60)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 50)
    Executive VP, CFO & Treasurer
    Comp: $710.6k
  • Mr. David Colleran J.D. (Age 52)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $664.54k
  • Ms. Anne Nunes (Age 55)
    Senior VP & COO
  • Mr. Ian W. McLeod
    VP & Chief Accounting Officer
  • Mr. Mark Namaroff (Age 61)
    Executive Director of Investor Relations & Corporate Communications
  • Mr. James Chase
    Senior Vice President of International Sales & Marketing
  • Mr. Ben Joseph
    Vice President of Commercial & Corporate Development
  • Ms. Lisa Funiciello
    Vice President of Human Resources

ANIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for Anika Therapeutics' stock. Their ANIK share price targets range from $22.00 to $37.00. On average, they anticipate the company's share price to reach $29.50 in the next year. This suggests a possible upside of 16.1% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2024?

Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK shares have increased by 12.1% and is now trading at $25.40.
View the best growth stocks for 2024 here
.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 766,100 shares, an increase of 32.4% from the February 29th total of 578,500 shares. Based on an average daily volume of 84,100 shares, the days-to-cover ratio is presently 9.1 days. Currently, 5.4% of the company's shares are sold short.
View Anika Therapeutics' Short Interest
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a negative net margin of 49.60% and a negative trailing twelve-month return on equity of 2.10%. During the same quarter in the prior year, the firm earned ($0.45) EPS.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, March, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $168.0 million-$173.0 million, compared to the consensus revenue estimate of $179.4 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Trigran Investments Inc. (14.61%), Dimensional Fund Advisors LP (5.61%), Vanguard Group Inc. (5.22%), Vanguard Group Inc. (5.22%), Capital Management Corp VA (2.43%) and Nuveen Asset Management LLC (1.81%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners